ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
CART-T cell therapy in young patients with relapsed/refractory ALL
Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany
HSCT: Donor selection for patients with ALL
Prof Sebastian Giebel - The Maria Skłodowska-Curie Institute of Oncology, Gliwic...
Therapy of Ph-positive adult ALL
Prof Oliver Ottmann - Cardiff University, Cardiff, UK
The role of blinatumomab followed by HSCT in paediatric patients with ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
Long-term outcomes of subjects with EBV driven PTLD following solid organ or all...
Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT afte...
Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA
KRd consolidation in MM patients with a positive PET-CT after standard first-lin...
Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway
Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse ...
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL
Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
Using bioinformatics and genomics to treat AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany